The renin-aldosterone paradox in POTS

The standard first-line advice for POTS — increase sodium intake to 3–5 grams daily, increase fluid intake to 2–3 liters — is based on a reasonable premise: POTS is associated with reduced plasma volume, and expanding plasma volume should improve venous return when upright, reducing the tachycardia that compensates for inadequate cardiac filling. Raj and colleagues at Vanderbilt published a 2005 paper in Circulation that confirms the volume deficit and reveals why the intake intervention produces inconsistent results. The problem is not the intake. It is the hormonal signaling that determines whether what you consume is retained or excreted. In a substantial proportion of POTS patients, that signaling is not functioning correctly.

What the Study Measured: Blood Volume and the Hormonal Response

Raj's team recruited POTS patients meeting standard diagnostic criteria and age- and sex-matched healthy controls. Total blood volume was measured using radiolabeled I-131 albumin dilution — the most accurate available method for quantifying both plasma volume and red cell mass simultaneously. Unlike hematocrit-based estimates, this technique directly measures the dilution of a known quantity of labeled protein to calculate plasma volume and derives red cell mass from the result.

Alongside blood volume, the team measured plasma renin activity and aldosterone levels at rest and during orthostatic challenge. Renin and aldosterone are the key hormones in the renin-angiotensin-aldosterone system (RAAS) — the body's primary mechanism for detecting volume deficits and signaling the kidneys to retain sodium and water.

The blood volume finding confirmed the clinical expectation: POTS patients had average total blood volume approximately 13% below predicted normal values based on body surface area. Plasma volume was reduced by roughly 12%, and red cell mass by approximately 14%. These are not trivial numbers. A 12% plasma volume reduction in an average adult represents several hundred milliliters of missing circulating fluid — a volume deficit that materially impairs the cardiac filling available when standing.

The Paradox: Volume Down, Hormones Not Responding

Normal RAAS physiology works as follows. When plasma volume falls, renal perfusion pressure drops. The juxtaglomerular cells of the kidney detect this drop and release renin. Renin cleaves angiotensinogen to angiotensin I, which ACE converts to angiotensin II. Angiotensin II stimulates the adrenal cortex to release aldosterone. Aldosterone acts on the distal nephron to increase sodium reabsorption, with water following osmotically. The loop closes: volume deficit is detected, sodium and water are retained, volume is restored toward normal.

In the Raj data, this corrective loop was not functioning. Despite documented volume deficits, plasma renin activity and aldosterone levels were inappropriately low relative to what the degree of volume reduction should have produced. The kidneys were not receiving the signal to retain sodium. The body was chronically volume-depleted without mounting the endocrine correction that should have followed from that depletion.

This is the renin-aldosterone paradox: volume is low, but the system responsible for detecting low volume and correcting it is not activating appropriately. The exact reason for the suppressed renin remains incompletely resolved in subsequent literature. Candidate mechanisms include elevated sympathetic norepinephrine suppressing renin release at the juxtaglomerular apparatus, altered renal perfusion dynamics, or dysfunction in the baroreceptors responsible for sensing renal perfusion pressure. What the data establish is the result: the signaling cascade is not working, and the volume deficit persists because of it.

Why Salt and Fluid Intake Has Inconsistent Effects

The rationale for high sodium intake in POTS is that if the kidneys retain sodium, water follows, and plasma volume expands. This is correct — when RAAS is functioning. Aldosterone-mediated sodium retention is how the body keeps the sodium you consume rather than excreting it. If you consume more sodium and your kidneys retain it under aldosterone's direction, plasma volume expands. If you consume more sodium but the RAAS is not signaling adequate retention, the kidneys excrete a large proportion of the additional sodium within hours, regardless of intake level.

For POTS patients with the renin-aldosterone paradox, this is not a compliance problem or a dosing problem. It is a mechanism mismatch. The intervention — high sodium intake — is asking the body to do something that requires RAAS activity it is not generating. The body eliminates what it is not signaled to retain.

This explains the clinical pattern many patients describe: they increase sodium intake substantially, experience modest initial benefit from the acute osmotic effect of a sodium load, and then find that the benefit does not persist, because the kidneys are not retaining the ongoing sodium intake at a rate that would sustain expanded plasma volume. The intervention is correct in direction; it is incomplete in mechanism.

Fludrocortisone: Bypassing the Broken Signal

Fludrocortisone, a synthetic mineralocorticoid, is among the first-line pharmacological treatments for POTS. Its mechanism is precisely relevant to the Raj finding: fludrocortisone acts on the same aldosterone receptors in the distal nephron to increase sodium reabsorption. It does not correct the upstream RAAS signaling problem. It bypasses it, providing the mineralocorticoid effect that the deficient aldosterone production should have been delivering.

This is why fludrocortisone sometimes succeeds where dietary sodium has not: it is operating at a different step in the pathway, substituting for the absent aldosterone rather than hoping that more substrate will overcome the signaling deficit. Understanding this difference — between providing more sodium to a kidney that is not receiving the signal to retain it, versus providing the retention signal directly — clarifies why these two interventions have different dose-response characteristics.

Exercise as the Second Pathway

The Raj data also clarify why exercise-driven plasma volume expansion provides a different kind of benefit than sodium and fluid intake. The albumin-mediated mechanism of exercise-induced plasma volume expansion operates through hepatic protein synthesis responding to cardiovascular demand — a pathway entirely independent of RAAS. Exercise drives albumin production, albumin pulls water into the vascular space through oncotic pressure, and plasma volume expands through a mechanism the defective renin-aldosterone loop cannot interfere with.

For POTS patients with the renin-aldosterone paradox, exercise-based volume expansion may be more durable than sodium-based volume expansion precisely because it does not rely on the signaling cascade that is failing. This is not an argument against sodium intake — it remains useful. It is an argument for not treating sodium intake as the only or primary volume restoration strategy, particularly for patients who have maximized it and still have inadequate volume.

What Evaluation Should Include

Measuring plasma renin activity and aldosterone during orthostatic challenge — not just blood pressure and heart rate — provides direct information about whether the RAAS is functioning appropriately for the patient's volume status. A patient with a documented volume deficit and appropriately elevated renin and aldosterone is failing to retain volume despite normal signaling: a different problem. A patient with a volume deficit and blunted renin and aldosterone has the Raj pattern and has a mechanistic rationale for mineralocorticoid supplementation that dietary modification alone cannot adequately replace.

If you have been on a high-sodium protocol for months with minimal sustained benefit, the renin-aldosterone paradox is a plausible explanation that your evaluation may not have tested for. The deficit is real. The correction mechanism is not functioning. Understanding which part of the volume regulation system is failing changes what the next intervention should be.